Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: A decision analysis model

Hepatology

Volumn 46, Issue 4, 2007, Pages 1049-1056

  Saab, Sammy ^a,c   Dong, Mamie H ^a   Joseph, Tom A ^a   Tong, Myron J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTHRACYCLINE; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; LAMIVUDINE; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; STEROID; VINBLASTINE; VINCRISTINE; VINDESINE;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; FOLLOW UP; HEPATITIS B; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DECISION SUPPORT TECHNIQUES; DOXORUBICIN; HEALTH CARE COSTS; HEPATITIS B; HUMANS; LAMIVUDINE; LIVER NEOPLASMS; LYMPHOMA; PREDNISOLONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 36349022770     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21783     Document Type: Article

References (53)

1. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004;350:1118-1129.
2. Lee WM. Hepatitis B virus infection. Med Prog 1997;337:1733-1745.
3. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. HEPATOLOGY 2006;43:209-220.
4. Xunrong L, Yan AW, Liang R, Lau GKK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy - pathogenesis and management. Rev Med Virol 2001;11:287-299.
5. Liang R, Lau GKK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999;17:394-398.
6. DeVita VT, Hubbard SM, Longo DL. The chemotherapy of lymphomas: looking back, moving forward - the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 1987;47:5810-5824.
7. Koak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963-977.
8. Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
9. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′- thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991;88:8495-8499.
10. Ahmed A, Keeffe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 1999;94:249-251.
11. Yeo W, Chan PKS, Chan HLY, Mo FKF, Johnson PJ. Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol 2001;65:473-477.
12. Li YH, He YF, Jiang WQ, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006;106:1320-1325.
13. Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004;83:270-275.
14. Idilman R, Arat M, Soydan E, Toruner M, Soykan I, Akbulut H, et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 2004;11:141-147.
15. Lau GKK, Yiu HHY, Fong DYT, Cheng HC, Au WY, Lai LSF, et al. Early is superior ro deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-1749.
16. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002;100:391-396.
17. Lee GW, Ryu MH, Lee JL, Oh S, Kim E, Lee JH, et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci 2003;18:849-854.
18. Lok AS, McMahon BJ. AASLD Practice Guidelines: chronic hepatitis B. HEPATOLOGY 2001;34:1225-1241.
19. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001;115:58-62.
20. Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2002;116:166-169.
21. Faggioli P, Paschale MD, Tocci A, Luoni M, Fava S, De Paoli A, et al. Acute hepatic toxicity during cyclic chemotherapy in non-Hodgkin's lymphoma. Haematologica 1997;82:38-42.
22. Yeo W, Chan PKS, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307.
23. Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B, et al. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. Haematologica 2003;88:1296-1303.
24. Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999;46:2925-2930.
25. Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-188.
26. Persico M, De Marino F, Russo GDG, Motante A, Rotoli B, Torella R, et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin's lymphoma. Blood 2002;99:724-725.
27. Fouillard L, Serfaty L, Gozlan J. Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2006;37:625-626.
28. Cortelezzi A, Vigano M, Zilioli VR, Fantini NN, Pasquini MC, Deliliers GL, et al. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with campath-1H. J Clin Virol 2006;35:467-469.
29. Enomoto M, Nishiguchi S, Seki S, Yamane T, Hino M. Adefovir dipoxil to prevent exacerbation of lamivudine-resistant hepatitis B infection during chemotherapy for non-Hodgkin's lymphoma. Am J Gastroenterol 2004;99:1619-1620.
30. Lok AS, McMahon BJ. AASLD Practice Guidelines: chronic hepatitis B: update of recommendations. HEPATOLOGY 2004;39:857-861.
31. Gauthier J, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999;180:1757-1762.
32. Hui CK, Cheung WWW, Au WY, Lie AK, Zhang HY, Yueng YH, et al. Hepatitis B teactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancies on completion of cytotoxic chemotherapy. Gut 2005;54:1597-1603.
33. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004;83:769-774.
34. PDR Staff. Red Book. 110th ed. Thomson Healthcare (Montvale, NJ); 2006.
35. Hoover D, Crystal S, Kumar R. Medical expenditures during the last year of medical expenditures during the last year of life: findings from the 1992-1996 Medicare current beneficiary survey. Health Serv Res 2002;37:1625-1642.
36. U.S. Department of Labor Bureau of Labor Statistics. Consumer price index calculator. Available at: http://www.bls.gov. Accessed May 2007.
37. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. JAMA 1996;276:1172-1177.
38. Petitti D. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. New York, NY: Oxford University Press; 2000.
39. Webster A, Brenner MK, Prentice HG, Griffiths PD. Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant 1989;4:207-208.
40. Mertens T, Kock J, Hampl W, Schlicht HJ, Tillmann HL, Oldhafer KJ, et al. Reactivated fulminant hepatitis B virus replication after bone marrow transplantation: clinical course and possible treatment with ganciclovir. J Hepatol 1996;25:968-971.
41. Yoshiba M, Sekiyama K, Sugata F, Okamoto H, Yamamoto K, Yotsumoto S. Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment. Dig Dis Sci 1992;37:1253-1259.
42. Peters MG, Hann HW, Martin P, Tillinget W, Reinisch W, Fueget GF, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resisrant chronic hepatitis B. Gastroenterology 2004;126:91-101.
43. Perillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD murant hepatitis B virus. Gastroenterology 2004;126:81-90.
44. Gerolami R, Bourliere M, Colson P, Halfon P, Borentain P, Henry M, et al. Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases. Antivir Ther 2006;11:1103-1106.
45. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE IV. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005;10:625-633.
46. Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004;15:1661-1666.
47. Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 2004;24:540-546.
48. Yeo W, Hui EP, Chan ATC, Ho WM, Lam KC, Chan PK, et al. Prevention of hepatitis B Reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 2005;28:379-384.
49. Tsai FC, Hseih HC, Chen DS, Shen JC, Chen DS. Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents. Dig Dis Sci 2006;51:1627-1632.
50. Murakami R, Amada N, Sato T, Orii T, Kikuchi H, Haga I, et al. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single center experience. Clin Transplant 2006;20:351-358.
51. Shitrit AB-G, Kramer MR, Bakal I, Morali G, Ari ZB, Shitrit D. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation. Ann Thorac Surg 2006;81:1851-1852.
52. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Fome M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-1365.
53. World Health Organization. Hepatitis B. Available at: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index1.html. Accessed May 2007.